IPO registrations (S-1, F-1) · Registrants
Protagenic Therapeutics, Inc.\new
- SEC CIK
- 1022899 · filings on EDGAR ↗
- Former names
- Atrinsic, Inc. (2009–2016); NEW MOTION, INC. (2007–2009); MPLC, Inc. (2005–2007); MILLBROOK PRESS INC (1996–2005)
- Registration
- Form S-1, first filed 2016-09-16, last 2024-12-20; 3 initial registrations, 7 amendments
- Outcome
- Final prospectus filed 2021-04-28; declared effective 2017-02-08
- Industry (SIC)
- Pharmaceutical Preparations 2834
- Incorporated in
- DE
- Business address
- 149 FIFTH AVENUE, SUITE 500, New York, NY 10010
- EIN
- 06-1390025
- Ticker
- PTIX (OTC)
- EDGAR entity type
- operating
- Insiders and CEO pay
- Protagenic Therapeutics, Inc.\new on the corporate pages
Offering terms
- Proposed price range
- $4.13–$4.17 per share (S-1/A filed 2021-04-26)
- Final price
- $4.98 per share, above the range (424B4 filed 2021-04-28)
- Shares sold
- 3,180,000
- Gross proceeds
- $15,836,400 before underwriting discounts and any over-allotment option
- Listing
- OTCQB under the symbol PTIX
- Lead underwriters
- The Benchmark Company; EF Hutton
- Syndicate
- Brookline Capital Markets, a division of Arcadia Securities, LLC (198,000); WestPark Capital, Inc (90,500)
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Form 5500 plan sponsor: ATRINSIC, INC. EXACT (EIN (EXACT))
- Form D issuer: Protagenic Therapeutics, Inc.\new EXACT (CIK (EXACT))
- SEC filer: Atrinsic, Inc. EXACT (CIK (EXACT))
- Person page: Garo H Armen Phd Fuzzy (officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director,Officer))
Filings 19
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2016-09-16 | S-1 | S-1 (registration) | Protagenic Therapeutics, Inc.\new | 0001437749-16-038794 ↗ |
| 2016-12-28 | S-1/A | S-1/A (amendment) | Protagenic Therapeutics, Inc.\new | 0001437749-16-043833 ↗ |
| 2017-01-27 | S-1/A | S-1/A (amendment) | Protagenic Therapeutics, Inc.\new | 0001437749-17-001259 ↗ |
| 2017-02-08 | EFFECT | EFFECT (declared effective) | Protagenic Therapeutics, Inc.\new | 9999999995-17-000322 ↗ |
| 2021-02-11 | S-1 | S-1 (registration) | Protagenic Therapeutics, Inc.\new | 0001493152-21-003410 ↗ |
| 2021-04-07 | S-1/A | S-1/A (amendment) | Protagenic Therapeutics, Inc.\new | 0001493152-21-008140 ↗ |
| 2021-04-09 | S-1/A | S-1/A (amendment) | Protagenic Therapeutics, Inc.\new | 0001493152-21-008441 ↗ |
| 2021-04-23 | S-1/A | S-1/A (amendment) | Protagenic Therapeutics, Inc.\new | 0001493152-21-009500 ↗ |
| 2021-04-26 | S-1/A | S-1/A (amendment) | Protagenic Therapeutics, Inc.\new | 0001493152-21-009608 ↗ |
| 2021-04-26 | S-1/A | S-1/A (amendment) | Protagenic Therapeutics, Inc.\new | 0001493152-21-009619 ↗ |
| 2021-04-26 | S-1MEF | S-1MEF (added securities) | Protagenic Therapeutics, Inc.\new | 0001493152-21-009799 ↗ |
| 2021-04-26 | EFFECT | EFFECT (declared effective) | Protagenic Therapeutics, Inc.\new | 9999999995-21-001560 ↗ |
| 2021-04-28 | 424B4 | 424B4 (final prospectus) | Protagenic Therapeutics, Inc.\new | 0001493152-21-009966 ↗ |
| 2021-04-28 | 424B4 | 424B4 (final prospectus) | Protagenic Therapeutics, Inc.\new | 0001493152-21-009968 ↗ |
| 2021-06-23 | EFFECT | EFFECT (declared effective) | Protagenic Therapeutics, Inc.\new | 9999999995-21-002472 ↗ |
| 2021-09-17 | EFFECT | EFFECT (declared effective) | Protagenic Therapeutics, Inc.\new | 9999999995-21-003572 ↗ |
| 2024-12-20 | S-1 | S-1 (registration) | Protagenic Therapeutics, Inc.\new | 0001493152-24-050846 ↗ |
| 2024-12-26 | EFFECT | EFFECT (declared effective) | Protagenic Therapeutics, Inc.\new | 9999999995-24-003922 ↗ |
| 2025-01-08 | EFFECT | EFFECT (declared effective) | Protagenic Therapeutics, Inc.\new | 9999999995-25-000057 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2021-04-26 | S-1/A | registration statement | $4.13–$4.17 | 2,650,000 | - | Nasdaq PTIX | 2 | primary document; range, price sentence, shares headline, proceeds computed, price outside the range dropped | document ↗ | |
| 2021-04-28 | 424B4 | final prospectus | $4.98 | 3,180,000 | $15,836,400 | OTCQB PTIX | 4 | primary document; price line, shares headline, proceeds computed, underwriting table 2 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| KIER ISAAC | Director | 1 | 2006 | ||
| Banon Sid | Other | 1 | 2006 | ||
| CHAZEN JEROME A | Director | 5 | 2006–2010 | ||
| ELLIN ROBERT S | Director; Director,Officer,TenPercentOwner; Director,TenPercentOwner; TenPercentOwner | CFO,COO and Secretary | 12 | 2006–2010 | |
| Regenstein Barry | Director | 2 | 2006–2007 | ||
| Trinad Capital Master Fund Ltd. | Director,TenPercentOwner; TenPercentOwner | CEO and President | 11 | 2006–2010 | |
| Wolf Jay | Director,Officer,TenPercentOwner; TenPercentOwner | 10 | 2006–2008 | ||
| Akres Jeffrey | TenPercentOwner | 1 | 2007 | ||
| Katz Burton | Director,Officer | Chief Executive Officer | 4 | 2007–2009 | |
| Larner Drew | Director | 2 | 2007 | ||
| Legator Allan | Officer | CFO and Secretary; CFO & Secretary | 2 | 2007–2008 | |
| MPLC Holdings LLC | TenPercentOwner | 1 | 2007 | ||
| MUSCI RAYMOND | Director,Officer | Exec VP, Corporate Development; President | 3 | 2007–2010 | |
| WALKER SCOTT | Officer,TenPercentOwner | Chief Marketing Officer | 2 | 2007 | |
| Trinad Advisors GP, LLC | TenPercentOwner | 1 | 2007 | ||
| Trinad Capital L.P. | TenPercentOwner | 9 | 2007–2010 | ||
| Trinad Management, LLC | Director,TenPercentOwner; TenPercentOwner | 10 | 2007–2010 | ||
| Klier Gil | Director | 2 | 2007 | ||
| SWENSON SUSAN | Officer | Chief Operating Officer | 2 | 2007–2008 | |
| Trinad Advisors II, LLC | TenPercentOwner | 9 | 2007–2010 | ||
| BURSTEIN LAWRENCE | Director | 4 | 2008–2010 | ||
| HARVEY DANIEL | Officer | Chief Financial Officer | 2 | 2008 | |
| MACHINIST ROBERT | Director | 2 | 2008 | ||
| STOLLMAN ANDREW | Director,Officer; Officer | President | 3 | 2008–2009 | |
| DESTAR, LLC | TenPercentOwner | 1 | 2008 | ||
| Smith David E | TenPercentOwner | 1 | 2008 | ||
| ZAREF ANDREW | Officer | Chief Financial Officer | 3 | 2008–2009 | |
| SCHWARTZ JEFFREY A | Director; Director,Officer | Chief Executive Officer | 3 | 2008–2010 | |
| DYNE MARK | Director; Director,TenPercentOwner | 5 | 2008–2010 | ||
| Greenberger Zachary | Officer | Chief Technology Officer | 2 | 2009 | |
| Plotts Thomas | Officer | Chief Financial Officer; Interim CFO | 4 | 2010 | |
| Goldfarb Stuart | Director | 1 | 2010 | ||
| BRILLIANT DIGITAL ENTERTAINMENT INC | TenPercentOwner | 2 | 2010–2011 | ||
| Siegel Sharon | Officer | Chief Marketing Officer | 1 | 2011 | |
| Fong Nathan Yu-Gai | Officer | Chief Financial Officer | 1 | 2011 | |
| Gildea Edward J | Director,Officer | Chief Executive Officer | 1 | 2014 | |
| Horin David J | Officer | Chief Financial Officer | 1 | 2014 | |
| SCHECHTER JONATHAN | Director | 1 | 2014 | ||
| ARMEN GARO H | Director,Officer; Director,Officer,TenPercentOwner | EXEC. CHAIR & PRINCIPAL OFF; EXEC. CHAIR & PRINCIPAL OFF.; Executive Chairman; See Remarks | 14 | 2016–2026 | person page Fuzzy |
| Arrow Alexander K. | Officer | Chief Financial Officer | 14 | 2016–2024 | |
| Barrage Khalil | Director | 9 | 2016–2024 | ||
| Ekizian Gregory | Director | 2 | 2016 | ||
| Stein Robert Benjamin | Director | 5 | 2016–2024 | ||
| Ziroyan Robert | Officer | COO / Interim President | 1 | 2016 | |
| Silverman Joshua | Director | 4 | 2016–2020 | ||
| Corvese Brian | Director | 3 | 2017–2024 | ||
| Buell Jennifer | Director | 2 | 2020–2024 | ||
| WRIGHT TIMOTHY R | Director | 1 | 2024 | ||
| EMC2 Capital LLC | Director,Officer,TenPercentOwner | ex CEO | 1 | 2025 | |
| EVANS BARRETT | Director,Officer,TenPercentOwner | ex CEO | 1 | 2025 | |
| Mammoth Crest Capital LLC | Director,Officer,TenPercentOwner | ex CEO | 1 | 2025 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2019-10-29 | Protagenic Therapeutics, Inc.\new | Biotechnology | $2,500,000 | $670,000 | 14 | 3 |
| 2016-02-23 | Atrinsic, Inc. | Biotechnology | $5,500,000 | $5,135,575 | 49 | 3 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Form D issuer | Protagenic Therapeutics, Inc.\new | NY | Form D private offerings | CIK (EXACT) |
| IPO registrant | MiNK Therapeutics, Inc. | NY | IPO registrations (S-1, F-1) | same street address and ZIP code, 149 FIFTH AVE STE 500 10010 (FUZZY: a shared address, not proof of a shared organization) |
| SEC filer | Protagenic Therapeutics, Inc. ew | SEC filers (EDGAR) | CIK (EXACT) | |
| Form 5500 plan sponsor | ATRINSIC, INC. | EIN (EXACT) | ||
| Person page | Garo H Armen Phd | People (Form 990 officers, directors and employees) | officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director,Officer) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry Pharmaceutical Preparations, NY first:
- TG THERAPEUTICS, INC. NY
- SIGA TECHNOLOGIES INC NY
- SEELOS THERAPEUTICS, INC. NY
- XTL BIOPHARMACEUTICALS LTD NY
- PENWEST PHARMACEUTICALS CO NY
- CHEMBIO DIAGNOSTICS, INC. NY
- EYETECH PHARMACEUTICALS INC NY
- INNOVATIVE DRUG DELIVERY SYSTEMS INC NY
- EON LABS INC NY
- ORAMED PHARMACEUTICALS INC. NY
In other datasets, the same topic (Health) in NY:
- Nonprofit: AABR FOUNDATION INC (Nonprofits (IRS Form 990))
Interests: Pharmaceutical Preparations · Health